Rhythm Pharmaceuticals Inc (RYTM) is trading -7% lower at $24.72 today.

Rhythm Pharmaceuticals Inc has been trading between a 52-week high of $27.29 and a 52-week low of $3.04. The stock has a market cap of $1.25 Billion.

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Benzinga 08-16-22

Tuesday’s Top Analyst Upgrades and Downgrades: Alphabet, Amazon, DraftKings, Dun & Bradstreet, Lululemon Athletica, Western Digital and More – 24/7 Wall St.
24/7 Wall street 08-09-22

Can Rhythm Pharmaceuticals Keep Up This Tempo?
The Street RealMoney 08-08-22

RYTM stock gains as Goldman upgrades on potential of wight loss agent (NASDAQ:RYTM)
Seeking Alpha 08-08-22

UPDATE: Goldman Sachs Upgrades Rhythm Pharmaceuticals to Buy
Investing.com 08-08-22